• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Disease characteristics and completion of treatment in patients with metastatic castration-resistant prostate cancer treated with radium-223 in an international early access program

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    saad.pdf
    Size:
    863.1Kb
    Format:
    PDF
    Description:
    Full text, Open Access article
    Download
    Authors
    Saad, F
    Gillessen, Silke
    Heinrich, D
    Keizman, D
    O'Sullivan, J
    Nilsson, S
    Miller, K
    Wirth, M
    Reeves, J
    Seger, M
    Carles, J
    Heidenreich, A
    Show allShow less
    Affiliation
    Department of Urology, University of Montreal Hospital Center, Montreal, Quebec, Canada
    Issue Date
    2019
    
    Metadata
    Show full item record
    Abstract
    BACKGROUND: Radium-223 is approved by the US Food and Drug Administration and European Medicines Agency for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are currently no markers for selecting patients most likely to complete radium-223 treatment. PATIENTS AND METHODS: In this phase IIIb, international, single-arm study, patients received radium-223, 55 kBq/kg, every 4 weeks for </=6 cycleS Primary end points were safety and overall survivaL In post hoc analyses patients were grouped according to number of radium-223 injections received (1-4 or 5-6). Associations between baseline covariates and number of injections were investigated. RESULTS: Of 696 eligible patients, 473 (68%) had received 5 to 6 radium-223 injections and 223 (32%) 1 to 4 injectionS Patients with less pain (moderate-severe vS none-mild, odds ratio [OR], 0.41; P < .0001), lower Eastern Cooperative Oncol.ogy Group performance status (>/=2 vS 0-1, OR, 0.51; P = .0074), lower prostate-specific antigen level (>141 mug/L vS </=141 mug/L, OR, 0.40; P < .0001), and higher hemoglobin level (<10 g/dL vS >/=10 g/dL, OR, 0.50; P = .0206) were more likely to receive 5 to 6 than 1 to 4 injectionS Median overall survival was not reached and was 6.3 months (95% confidence interval, 5.4-7.4) in patients who had received 5 to 6 and 1 to 4 radium-223 injections, respectivelY Adverse events were less common in patients who received 5 to 6 than 1 to 4 injections; anemia was reported in 87 (18%) and 64 (29%) patients, respectively. CONCLUSION: Patients with less advanced mCRPC are more likely to receive 5 to 6 radium-223 injections and to achieve better overall survivaL Consideration of baseline and disease characteristics is recommended before initiation of radium-223 treatment.
    Citation
    Saad F, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Nilsson S, et al. Disease characteristics and completion of treatment in patients with metastatic castration-resistant prostate cancer treated with radium-223 in an international early access program. Clin Genitourin Cancer. 2019.
    Journal
    Clinical Genitourinary Cancer
    URI
    http://hdl.handle.net/10541/622037
    DOI
    10.1016/j.clgc.2019.05.012
    PubMed ID
    31311763
    Additional Links
    https://dx.doi.org/10.1016/j.clgc.2019.05.012
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.clgc.2019.05.012
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    • Authors: Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM, Radium-223 International Early Access Program Investigators
    • Issue date: 2016 Sep
    • Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    • Authors: Heidenreich A, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Carles J, Wirth M, Miller K, Reeves J, Seger M, Nilsson S, Saad F
    • Issue date: 2019 Jan 7
    • Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    • Authors: Sartor O, Heinrich D, Mariados N, Méndez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo J, Trandafir L, Wagner V, Li R, Nordquist LT
    • Issue date: 2019 Oct
    • Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    • Authors: Uemura H, Uemura H, Nagamori S, Wakumoto Y, Kimura G, Kikukawa H, Yokomizo A, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Akagawa T, Matsubara N
    • Issue date: 2019 May
    • Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
    • Authors: Carles J, Castellano D, Méndez-Vidal MJ, Mellado B, Saez MI, González Del Alba A, Perez-Gracia JL, Jimenez J, Suárez C, Sepúlveda JM, Manneh R, Porras I, López C, Morales-Barrera R, Arranz JÁ
    • Issue date: 2018 Dec
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.